Drug-Resistant Leishmania tropica in Iranian Cutaneous Leishmaniasis
Author Information
Author(s): Ramtin Hadighi, Mehdi Mohebali, Marc Ouellette
Hypothesis
Is the increased incidence of Glucantime-unresponsive cutaneous leishmaniasis in Iran correlated with parasite resistance to the drug?
Conclusion
The study found that treatment failure in cutaneous leishmaniasis in Iran is due to Glucantime-resistant parasites.
Supporting Evidence
- 20 out of 185 patients did not respond to Glucantime treatment.
- Parasites from unresponsive patients were found to be 4-fold less susceptible to Glucantime than those from responsive patients.
- 28 of the isolates were identified as L. tropica, indicating a prevalence of this species in drug resistance.
Takeaway
Some people in Iran are getting sick from a skin disease because the medicine isn't working anymore, and that's because the germs have learned to resist the medicine.
Methodology
The researchers isolated Leishmania parasites from skin lesions of untreated patients and tested their resistance to Glucantime in mouse macrophages.
Limitations
The study primarily focused on a specific region in Iran, which may limit the generalizability of the findings.
Participant Demographics
Patients living in Mashhad, Iran, where cutaneous leishmaniasis is endemic.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website